Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin in type 2 diabetes with moderate to severe renal impairment
2009-016971-31Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2010
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin with Placebo then glimepiride (2 arms). Primary endpoint: Change from baseline in HbA1c after 12 weeks of treatment. Started Jan 2010; status: completed.
02
Drugs
linagliptinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016971-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016971-31.